What exactly is Lynparza? what is its main use

Olaparib is an oral targeted anti-cancer drug that is a "polyadenosine diphosphate ribose polymerase" inhibitor, referred to as a PARP inhibitor. This class of drugs works by blocking the ability of tumor cells to repair their own DNA, specifically targeting cancer cells with inherent DNA repair defects, such as patients with BRCA1 or BRCA2 mutations. Lynparib is the world's first PARP inhibitor approved for clinical treatment.

From the perspective of its mechanism of action,PARP is a key DNA repair enzyme in cells. It is involved in repairing single-stranded DNA damage caused by cell replication or external environment. Tumor cells carrying BRCA mutations are unable to effectively repair double-stranded DNA damage. When inhibited by PARP, they will completely lose their DNA repair ability, eventually leading to cell death. Therefore, olaparib can highly selectively "starve" cancer cells while minimizing damage to normal cells. It is a relatively mild and precise category of current anti-tumor drugs.

Olaparib's clinical indications have expanded from the original ovarian cancer to a variety of solid tumors. Specifically, it is first used for the maintenance treatment of patients with platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, and has the advantage of significantly extending the disease progression-free period in such patients. Secondly, olaparib has also been approved for the treatment of patients with HER2-negative metastatic breast cancer carrying germline BRCA mutations. This type of breast cancer often has treatment bottlenecks in traditional chemotherapy, and olaparib provides new treatment hope.

In addition to female cancers, olaparib is also indicated for male patients, specifically metastatic castration-resistant prostate cancer (mCRPC) with HRR gene defects. In addition, it is also used to treat metastatic pancreatic cancer carrying BRCA mutations. This indication is of particular clinical significance because pancreatic cancer has a poor prognosis and few treatment options. Lynparza has brought important therapeutic breakthroughs to patients with some genotypes.

Reference materials:https://www.lynparza.com/